Omalizumab for severe allergic asthma: 7 years and open questions

Abstract

Anti-IgE treatment for severe allergic asthma has been available for more than seven years now. This treatment has clear clinical benefits and a good safety record. However, important questions concerning long-term dosing and treatment duration remain unanswered. This paper discusses the available information concerning the long-term use of omalizumab. © 2014 S. Karger AG, Basel.